 Ragesh Thandassery
Concepts (200)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Neoplasms | 6 | 2023 | 352 | 2.870 |
Why?
| | Carcinoma, Hepatocellular | 5 | 2023 | 203 | 2.790 |
Why?
| | Pancreatitis | 6 | 2019 | 58 | 2.570 |
Why?
| | Liver Cirrhosis | 6 | 2022 | 216 | 1.800 |
Why?
| | Hepatitis C, Chronic | 3 | 2020 | 89 | 1.270 |
Why?
| | APACHE | 3 | 2014 | 24 | 1.090 |
Why?
| | Common Bile Duct | 2 | 2014 | 10 | 0.990 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2023 | 12 | 0.950 |
Why?
| | Pancreatitis, Acute Necrotizing | 2 | 2014 | 6 | 0.940 |
Why?
| | Multiple Organ Failure | 2 | 2014 | 56 | 0.920 |
Why?
| | End Stage Liver Disease | 1 | 2023 | 43 | 0.910 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 5 | 2019 | 87 | 0.900 |
Why?
| | Hepatitis, Alcoholic | 1 | 2021 | 9 | 0.800 |
Why?
| | Sarcopenia | 1 | 2022 | 83 | 0.780 |
Why?
| | Kidney Diseases | 2 | 2016 | 293 | 0.760 |
Why?
| | Severity of Illness Index | 5 | 2023 | 1084 | 0.760 |
Why?
| | Antiviral Agents | 3 | 2020 | 188 | 0.690 |
Why?
| | Ribavirin | 1 | 2017 | 16 | 0.610 |
Why?
| | Ventricular Dysfunction | 1 | 2017 | 10 | 0.610 |
Why?
| | Interferon-alpha | 1 | 2017 | 50 | 0.610 |
Why?
| | Hypotension | 2 | 2017 | 67 | 0.600 |
Why?
| | Colonic Diseases | 1 | 2016 | 13 | 0.570 |
Why?
| | Intestinal Obstruction | 2 | 2013 | 37 | 0.560 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2016 | 24 | 0.560 |
Why?
| | Colon | 1 | 2016 | 110 | 0.540 |
Why?
| | Pancreatic Diseases | 2 | 2012 | 16 | 0.520 |
Why?
| | Humans | 35 | 2023 | 54284 | 0.510 |
Why?
| | Gastric Outlet Obstruction | 1 | 2014 | 6 | 0.510 |
Why?
| | Duodenal Diseases | 1 | 2014 | 9 | 0.510 |
Why?
| | Adult | 17 | 2021 | 14207 | 0.500 |
Why?
| | Hematoma | 1 | 2014 | 60 | 0.490 |
Why?
| | Colic | 1 | 2014 | 3 | 0.490 |
Why?
| | Ascariasis | 1 | 2014 | 4 | 0.490 |
Why?
| | Echocardiography | 1 | 2017 | 392 | 0.490 |
Why?
| | Biliary Tract Diseases | 1 | 2014 | 12 | 0.490 |
Why?
| | Sphincterotomy, Endoscopic | 1 | 2014 | 15 | 0.480 |
Why?
| | Choledocholithiasis | 1 | 2014 | 12 | 0.480 |
Why?
| | Tuberculosis, Hepatic | 1 | 2013 | 1 | 0.470 |
Why?
| | Middle Aged | 14 | 2023 | 13088 | 0.470 |
Why?
| | Endometriosis | 1 | 2013 | 16 | 0.460 |
Why?
| | Acute Disease | 4 | 2017 | 403 | 0.460 |
Why?
| | Intestinal Perforation | 3 | 2019 | 26 | 0.430 |
Why?
| | Intestines | 1 | 2014 | 204 | 0.430 |
Why?
| | Intestine, Small | 1 | 2013 | 123 | 0.430 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2012 | 75 | 0.420 |
Why?
| | Colonoscopy | 4 | 2016 | 105 | 0.410 |
Why?
| | Pancreatitis, Chronic | 1 | 2011 | 10 | 0.410 |
Why?
| | Abdominal Abscess | 1 | 2011 | 13 | 0.410 |
Why?
| | Calcinosis | 1 | 2011 | 61 | 0.400 |
Why?
| | Female | 19 | 2021 | 28441 | 0.380 |
Why?
| | Predictive Value of Tests | 4 | 2021 | 1048 | 0.360 |
Why?
| | Constriction, Pathologic | 3 | 2014 | 104 | 0.360 |
Why?
| | Male | 16 | 2017 | 27334 | 0.340 |
Why?
| | Prognosis | 3 | 2022 | 2118 | 0.320 |
Why?
| | Risk Factors | 5 | 2021 | 3935 | 0.320 |
Why?
| | Kaplan-Meier Estimate | 2 | 2023 | 514 | 0.310 |
Why?
| | Endosonography | 5 | 2014 | 96 | 0.300 |
Why?
| | Treatment Outcome | 5 | 2023 | 5604 | 0.300 |
Why?
| | Hepacivirus | 2 | 2017 | 127 | 0.270 |
Why?
| | Obesity | 1 | 2013 | 1202 | 0.260 |
Why?
| | Drainage | 3 | 2020 | 79 | 0.260 |
Why?
| | Chi-Square Distribution | 3 | 2014 | 318 | 0.240 |
Why?
| | Time Factors | 4 | 2016 | 3213 | 0.240 |
Why?
| | Biopsy | 2 | 2016 | 692 | 0.240 |
Why?
| | Ultrasonography, Interventional | 3 | 2012 | 146 | 0.220 |
Why?
| | Prospective Studies | 3 | 2014 | 2604 | 0.220 |
Why?
| | Hepatectomy | 1 | 2022 | 33 | 0.210 |
Why?
| | Odds Ratio | 2 | 2014 | 604 | 0.200 |
Why?
| | Hepatitis B, Chronic | 1 | 2021 | 15 | 0.200 |
Why?
| | Hepatitis B | 1 | 2021 | 27 | 0.200 |
Why?
| | Cholestasis, Intrahepatic | 1 | 2021 | 8 | 0.200 |
Why?
| | Neoplasm Staging | 1 | 2023 | 806 | 0.190 |
Why?
| | Hepatitis E | 1 | 2020 | 5 | 0.190 |
Why?
| | Hepatitis E virus | 1 | 2020 | 9 | 0.190 |
Why?
| | Disease Outbreaks | 1 | 2021 | 124 | 0.190 |
Why?
| | Disease Progression | 2 | 2014 | 913 | 0.190 |
Why?
| | Cholecystitis, Acute | 1 | 2020 | 11 | 0.180 |
Why?
| | Diagnosis, Differential | 3 | 2013 | 1136 | 0.180 |
Why?
| | Gallbladder | 1 | 2020 | 24 | 0.180 |
Why?
| | Retrospective Studies | 4 | 2023 | 6432 | 0.180 |
Why?
| | Stents | 4 | 2020 | 375 | 0.180 |
Why?
| | Cholecystitis | 1 | 2019 | 13 | 0.180 |
Why?
| | Cholangitis | 1 | 2019 | 11 | 0.180 |
Why?
| | Postoperative Complications | 2 | 2019 | 1033 | 0.180 |
Why?
| | Aged | 6 | 2023 | 10054 | 0.180 |
Why?
| | Fatty Liver | 1 | 2021 | 129 | 0.180 |
Why?
| | Postoperative Hemorrhage | 1 | 2019 | 53 | 0.180 |
Why?
| | Image-Guided Biopsy | 2 | 2021 | 35 | 0.170 |
Why?
| | Adrenal Cortex Hormones | 2 | 2016 | 95 | 0.160 |
Why?
| | Liver Transplantation | 1 | 2020 | 160 | 0.160 |
Why?
| | Pancreatic Ducts | 2 | 2019 | 11 | 0.160 |
Why?
| | Area Under Curve | 1 | 2017 | 205 | 0.150 |
Why?
| | Globulins | 1 | 2016 | 1 | 0.150 |
Why?
| | Erythrocyte Indices | 1 | 2016 | 8 | 0.150 |
Why?
| | Liver Function Tests | 1 | 2016 | 43 | 0.140 |
Why?
| | Platelet Count | 1 | 2016 | 77 | 0.140 |
Why?
| | Abdomen | 2 | 2014 | 83 | 0.140 |
Why?
| | Hepatitis, Autoimmune | 1 | 2016 | 29 | 0.140 |
Why?
| | Pregnancy Complications | 1 | 2021 | 384 | 0.140 |
Why?
| | Prednisolone | 1 | 2016 | 57 | 0.140 |
Why?
| | Vinblastine | 1 | 2016 | 41 | 0.140 |
Why?
| | Gastrointestinal Agents | 1 | 2016 | 36 | 0.140 |
Why?
| | Hepatorenal Syndrome | 1 | 2016 | 15 | 0.140 |
Why?
| | Colonic Neoplasms | 2 | 2014 | 164 | 0.140 |
Why?
| | ROC Curve | 1 | 2016 | 259 | 0.130 |
Why?
| | Creatinine | 1 | 2016 | 169 | 0.130 |
Why?
| | Intestinal Polyps | 1 | 2015 | 9 | 0.130 |
Why?
| | Glomerular Filtration Rate | 1 | 2016 | 138 | 0.130 |
Why?
| | Rectum | 1 | 2015 | 51 | 0.130 |
Why?
| | Rectal Neoplasms | 1 | 2015 | 51 | 0.130 |
Why?
| | Lipoma | 1 | 2014 | 21 | 0.130 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 426 | 0.130 |
Why?
| | Recurrence | 2 | 2014 | 690 | 0.130 |
Why?
| | Genotype | 1 | 2016 | 599 | 0.130 |
Why?
| | Enema | 1 | 2014 | 8 | 0.120 |
Why?
| | Liver | 1 | 2021 | 1225 | 0.120 |
Why?
| | Subcutaneous Emphysema | 1 | 2014 | 9 | 0.120 |
Why?
| | Bacterial Translocation | 1 | 2014 | 23 | 0.120 |
Why?
| | Scrotum | 1 | 2014 | 34 | 0.120 |
Why?
| | Antioxidants | 1 | 2016 | 297 | 0.120 |
Why?
| | India | 1 | 2013 | 79 | 0.120 |
Why?
| | Blood Platelets | 1 | 2016 | 269 | 0.120 |
Why?
| | Cholecystectomy | 1 | 2014 | 32 | 0.120 |
Why?
| | Colitis, Ulcerative | 1 | 2014 | 52 | 0.120 |
Why?
| | Jaundice | 1 | 2013 | 19 | 0.120 |
Why?
| | Adenoma | 1 | 2015 | 142 | 0.120 |
Why?
| | Portal Vein | 1 | 2013 | 30 | 0.110 |
Why?
| | Catheterization | 1 | 2014 | 108 | 0.110 |
Why?
| | Young Adult | 4 | 2021 | 4318 | 0.110 |
Why?
| | Organ Dysfunction Scores | 1 | 2012 | 17 | 0.110 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1089 | 0.110 |
Why?
| | Glasgow Coma Scale | 1 | 2012 | 48 | 0.110 |
Why?
| | Surgery, Computer-Assisted | 1 | 2013 | 53 | 0.110 |
Why?
| | Double-Balloon Enteroscopy | 1 | 2012 | 2 | 0.110 |
Why?
| | Pyloric Antrum | 1 | 2012 | 9 | 0.110 |
Why?
| | Learning Curve | 1 | 2012 | 22 | 0.110 |
Why?
| | Abdominal Pain | 1 | 2013 | 77 | 0.110 |
Why?
| | Stomach Diseases | 1 | 2012 | 15 | 0.110 |
Why?
| | Choristoma | 1 | 2012 | 22 | 0.110 |
Why?
| | Pancreatic Pseudocyst | 1 | 2012 | 7 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2014 | 643 | 0.110 |
Why?
| | Lymphatic Diseases | 1 | 2012 | 24 | 0.110 |
Why?
| | Drug Delivery Systems | 1 | 2014 | 151 | 0.110 |
Why?
| | Pancreas | 1 | 2012 | 80 | 0.110 |
Why?
| | Granuloma | 1 | 2012 | 45 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 3 | 2013 | 1213 | 0.100 |
Why?
| | Bacterial Infections | 1 | 2012 | 105 | 0.100 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2012 | 85 | 0.100 |
Why?
| | Tuberculosis | 1 | 2012 | 104 | 0.100 |
Why?
| | Blood Pressure | 1 | 2014 | 587 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 2 | 2016 | 1604 | 0.100 |
Why?
| | Body Mass Index | 1 | 2013 | 713 | 0.090 |
Why?
| | Lymph Nodes | 1 | 2012 | 284 | 0.090 |
Why?
| | Stomach Neoplasms | 1 | 2012 | 173 | 0.090 |
Why?
| | Reproducibility of Results | 1 | 2013 | 1304 | 0.090 |
Why?
| | Melanoma | 1 | 2012 | 313 | 0.090 |
Why?
| | Hospitalization | 1 | 2012 | 705 | 0.080 |
Why?
| | Biopsy, Fine-Needle | 2 | 2012 | 116 | 0.050 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2021 | 31 | 0.050 |
Why?
| | Duodenoscopes | 1 | 2019 | 3 | 0.050 |
Why?
| | Disinfection | 1 | 2019 | 12 | 0.050 |
Why?
| | Metals | 1 | 2020 | 44 | 0.050 |
Why?
| | Equipment Contamination | 1 | 2019 | 26 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2020 | 130 | 0.040 |
Why?
| | Ultrasonography | 1 | 2021 | 480 | 0.040 |
Why?
| | Laparoscopy | 1 | 2021 | 188 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 142 | 0.040 |
Why?
| | Patient Selection | 1 | 2019 | 286 | 0.040 |
Why?
| | Protein-Lysine 6-Oxidase | 1 | 2016 | 2 | 0.040 |
Why?
| | Receptors, CCR2 | 1 | 2016 | 14 | 0.040 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2016 | 83 | 0.040 |
Why?
| | Elasticity Imaging Techniques | 1 | 2016 | 24 | 0.040 |
Why?
| | Vitamin D Deficiency | 1 | 2016 | 53 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2016 | 111 | 0.030 |
Why?
| | Risk Assessment | 1 | 2021 | 1361 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2016 | 158 | 0.030 |
Why?
| | Administration, Rectal | 1 | 2014 | 10 | 0.030 |
Why?
| | Colonic Polyps | 1 | 2014 | 43 | 0.030 |
Why?
| | Radiography, Abdominal | 1 | 2013 | 29 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 820 | 0.030 |
Why?
| | Pregnancy | 1 | 2021 | 2620 | 0.030 |
Why?
| | Dacarbazine | 1 | 2012 | 10 | 0.030 |
Why?
| | Cytokines | 1 | 2016 | 676 | 0.030 |
Why?
| | Mediastinum | 1 | 2012 | 27 | 0.030 |
Why?
| | Catheters, Indwelling | 1 | 2012 | 68 | 0.030 |
Why?
| | Inflammation | 1 | 2016 | 674 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 232 | 0.030 |
Why?
| | Hodgkin Disease | 1 | 2012 | 51 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 256 | 0.030 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2012 | 63 | 0.030 |
Why?
| | Sarcoidosis | 1 | 2012 | 44 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2016 | 958 | 0.020 |
Why?
| | Mycobacterium tuberculosis | 1 | 2012 | 212 | 0.020 |
Why?
| | Cisplatin | 1 | 2012 | 352 | 0.020 |
Why?
| | Adolescent | 2 | 2012 | 6897 | 0.020 |
Why?
| | Apoptosis | 1 | 2016 | 1300 | 0.020 |
Why?
| | Length of Stay | 1 | 2012 | 683 | 0.020 |
Why?
| | Child | 1 | 2020 | 7341 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 1056 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2012 | 2387 | 0.020 |
Why?
|
|
Thandassery's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|